scholarly journals Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale

2017 ◽  
Vol Volume11 ◽  
pp. 923-937 ◽  
Author(s):  
Sayf A Yassin ◽  
Vanita R Aroda
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Evidence ◽  
Dipeptidyl Peptidase ◽  
Dipeptidyl Peptidase 4 ◽  
Sodium Glucose Cotransporter ◽  
Dipeptidyl Peptidase 4 Inhibitors

scholarly journals Semaglutide (Rybelsus)

2021 ◽  
Vol 1 (6) ◽  
Author(s):  
Reimbursement Team
Keyword(s):  
Type 2 Diabetes ◽  
Treatment Cost ◽  
Clinical Evidence ◽  
Dipeptidyl Peptidase 4 ◽  
Sodium Glucose Cotransporter ◽  
Dipeptidyl Peptidase 4 Inhibitors ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
High Treatment

Clinical evidence suggests that Rybelsus should be reimbursed to treat type 2 diabetes in adults if it is used in addition to metformin or other antihyperglycemic agents and does not cost more than glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and sodium-glucose cotransporter-2 inhibitors. Rybelsus is more costly than most similar diabetes treatments. Rybelsus is expected to increase budgets by more than $38 million over 3 years. To account for the high treatment cost, the price of Rybelsus should be reduced. If Rybelsus is not reimbursed as an add-on treatment for patients with type 2 diabetes, there are several other alternative treatments available for these patients.

Sign in / Sign up

Export Citation Format

Share Document